Kiadis Pharma announces it raised an addi­tion­al € 2.0 mil­lion via exer­cise of the Over-Allotment Option and the end of the sta­bil­i­sa­tion peri­od in rela­tion to its ini­tial pub­lic offer­ing

Amsterdam, the Netherlands, July 31, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Euronext Brussels: KDS), a recent­ly-list­ed clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive T-cell immunother­a­py treat­ments for blood can­cers and inher­it­ed blood dis­or­ders, today announces the par­tial exer­cise of the Over-Allotment Option by Kempen & Co N.V. act­ing on behalf of the Underwriters and the end of the sta­bil­i­sa­tion peri­od in rela­tion to its ini­tial pub­lic offer­ing (the “IPO” or the “Offering”).
Kiadis Pharma had grant­ed the Stabilisation Manager an option to pur­chase up to 392,045 addi­tion­al shares at the Offer Price of EUR 12.50 to cov­er poten­tial over-allot­ments or short posi­tions in con­nec­tion with the Offering, which option was exer­cis­able for a peri­od of 30 cal­en­dar days as from the first day of list­ing of the shares on Euronext Amsterdam and Euronext Brussels (i.e. 2 July 2015) (the “Over-Allotment Option”)
On 31 July 2015 the Stabilisation Manager exer­cised the Over-Allotment option for 163,500 shares, rais­ing addi­tion­al gross pro­ceeds of € 2.0 mil­lion for Kiadis Pharma. As a result, the total num­ber of shares sold by Kiadis Pharma in the IPO amounts to 2,777,136 shares, rep­re­sent­ing total gross pro­ceeds of € 34.7 mil­lion from the Offering.
The sta­bil­i­sa­tion peri­od com­menced on 2 July 2015 and end­ed on 31 July 2015. The new shares will be list­ed on Euronext Amsterdam and Euronext Brussels on or about 5 August 2015 and rank pari pas­su with the exist­ing shares.

Leave a Reply

Your email address will not be published. Required fields are marked *